SPDR SERIES TRUST's SPDR(R) S&P(R) Biotech ETF (XBI) has disclosed 154 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2022-12-31. The current portfolio value is calculated to be $8.09 Bil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 21%.
SPDR(R) S&P(R) Biotech ETF (XBI)'s
Total Assets is $8.78 Bil , Total Liabilities is $693.49 Mil , Net Assets is $8.09 Bil.
In SPDR(R) S&P(R) Biotech ETF (XBI)'s current portfolio as of 2022-12-31, the top 5 holdings are
Madrigal Pharmaceuticals Inc (MDGL), Arrowhead Pharmaceuticals Inc (ARWR), Cytokinetics Inc (CYTK), Akero Therapeutics Inc (AKRO) and Altimmune Inc (ALT),
not including call and put options.
SPDR(R) S&P(R) Biotech ETF (XBI) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for SPDR(R) S&P(R) Biotech ETF (XBI), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for SPDR(R) S&P(R) Biotech ETF (XBI), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for SPDR(R) S&P(R) Biotech ETF.